Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo

Zhang,Ling-li; Zhang,Jun; Shen,Lei; Xu,Xi-ming; Yu,Hong-gang

doi:10.3892/mmr.2013.1400

Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo

Authors:
- Ling-li Zhang
- Jun Zhang
- Lei Shen
- Xi-ming Xu
- Hong-gang Yu
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: March 28, 2013 https://doi.org/10.3892/mmr.2013.1400
Pages: 1387-1390

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (CDDP) is one of the most efficacious and widely used cytotoxic anticancer drugs used for the treatment of numerous types of cancer. However, its efficacy is limited as a result of acquired drug resistance. AKT overexpression may provide a potential mechanism leading to the resistance of human gastric cancer cells; however, the precise mechanism of the development of CDDP drug resistance remains uncertain. In the present study, we demonstrate that CDDP resistance is associated with AKT overexpression at the cellular and molecular level. We also observed that increased expression levels of AKT were sufficient to inhibit the resistance of gastric cancer cells to CDDP and that overexpressed AKT interacted with reactive oxygen species which were generated by CDDP. These results indicate that AKT activity is essential for the regulation of CDDP resistance in gastric cancer cells. Our results further demonstrate that AKT induces gastric cancer cells to become resistant to CDDP through the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. Taken together, these data support a potential role for AKT overexpression and the JAK2/STAT3 pathway in the development of CDDP drug resistance in human gastric cancer cells. We hypothesize that AKT may represent a future pharmacological target for the inhibition of CDDP resistance in human cancer.

View Figures

View References

1	Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW, et al: Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 345:745–748. 1995. View Article : Google Scholar : PubMed/NCBI
2	Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 21:54–59. 2003. View Article : Google Scholar
3	Yun J, Lee J, Park SH, Park JO, Park YS, Lim HY and Kang WK: A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer. 46:885–891. 2010. View Article : Google Scholar : PubMed/NCBI
4	Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ, Tamir A, Kerbel RS and Ben-David Y: Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene. 19:395–402. 2000. View Article : Google Scholar : PubMed/NCBI
5	Mizutani Y and Bonavida B: Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha. Cancer. 72:809–818. 1993. View Article : Google Scholar : PubMed/NCBI
6	Liu LZ, Zhou XD, Qian G, Shi X, Fang J and Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007. View Article : Google Scholar : PubMed/NCBI
7	Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ and de Vries EG: Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 52:6885–6889. 1992.PubMed/NCBI
8	Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 401:82–85. 1999. View Article : Google Scholar : PubMed/NCBI
9	Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
10	VanderWeele DJ, Zhou R and Rudin CM: Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther. 3:1605–1613. 2004.
11	Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells andpromotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61:3986–3997. 2001.PubMed/NCBI
12	Falasca M: PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 16:1410–1416. 2010. View Article : Google Scholar : PubMed/NCBI
13	Beckmann JS, Ye YZ, Anderson PG, et al: Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 375:81–88. 1994. View Article : Google Scholar : PubMed/NCBI
14	Liu QS, Zhang J, Liu M and Dong WG: Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer. Cancer Sci. 101:1807–1812. 2010. View Article : Google Scholar : PubMed/NCBI
15	Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M and Lin J: Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 20:407–416. 2000.PubMed/NCBI
16	Pommier Y, Sordet O, Antony S, Hayward RL and Kohn KW: Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene. 23:2934–2949. 2004. View Article : Google Scholar : PubMed/NCBI
17	Sekharam M, Zhao H, Sun M, Fang Q, Zhang Q, Yuan Z, Dan HC, Boulware D, Cheng JQ and Coppola D: Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 63:7708–7716. 2003.PubMed/NCBI
18	Kandasamy K and Srivastava RK: Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. 62:4929–4937. 2002.
19	Liu Y, Chen L, Ko TC, Fields AP and Thompson EA: Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene. 25:3565–3575. 2006. View Article : Google Scholar : PubMed/NCBI
20	Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol 3-kinase/AKT- mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 276:9817–9824. 2001. View Article : Google Scholar : PubMed/NCBI
21	Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN and Ueno NT: Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 67:5779–5788. 2007. View Article : Google Scholar : PubMed/NCBI
22	Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ and Spector NL: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation ofEGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 21:6255–6263. 2002. View Article : Google Scholar : PubMed/NCBI